tbuckley/cabot-search huggingface dataset:
Clinical Usefulness of Urinary Figlu Test in Megaloblastic Anaemias
Authors: A. Villamil, B. H. McCracken
Journal: BMJ (1963)

Further research might follow two lines.First, an attempt might be made to identify in more detail the family and community factors which lead to a demand for hospital care, and to study preventive measures and alternative ways of meeting needs.Second, an investi- gation of the trends in birth and death rates of sub- normal individuals would allow predictions to be made of the size of the future population from which hospital cases will arise. SummaryIn the Manchester Region the characteristics of the admissions and applications for admission of patients to mental deficiency hospitals for the period 1954-8 are described, together with those of a 20% sample of patients who left hospital during this period, and a 20% sample of hospital in-patients.About one-third of the admissions were of high grade, and many of these were young people without families who were committed to hospital for social, not medical, reasons.It was suggested that community care, with hostel accommodation and psychiatric and social support, might be considered as an alternative to hospital care, or as aftercare for those discharged, and might reduce the number of high-grade patients who spend all their adult lives in institutions.At present about one-third of the in-patients are of high grade, and in the past such patients, who were in hospital when they were 45 years old, had little chance of being discharged.Low-grade patients presented the most acute accom- modation problem, and the waiting-list for places for them rose throughout the period studied.Many of these patients were helpless children who actually needed nursing care, but it was questioned whether the hospitals were in a position to provide it for all those in need.The demand for hospital care for medium-grade patients, who made up nearly half of the hospital population, might be reduced by early community support for their families, and by training and the pro- vision of suitable jobs and hostels for the patients.The investigation of these possibilities and the study of the present prevalence of mental subnormality would render it possible to make meaningful predictions of the future need for services.
Anencephalic Organ Donor Program Suspended; Loma Linda Report Expected to Detail Findings
Authors: Marsha F. Goldsmith
Journal: JAMA (1988)

TAKING HEALTHY HEARTS from doomed babies born without a brain and giving them to brain-intact infants who had life-threatening congenital heart defects seemed like a good idea to the transplant team at Loma Linda (Calif) University Medical Center nine months ago. Suspension of the research protocol was announced last month after Leonard Bailey, MD, of the Department of Cardiothoracic Surgery and his colleagues failed for various reasons to perform even one such procedure, despite having a dozen anencephalic infants flown by Learjet to Loma Linda from around the country. <h3>Final Decision Pending</h3> Now the institution is rethinking its approach and is issuing a report said to contain "a wealth of information obtained from the study." A final decision on the future of the program will be made after all the information is evaluated. According to Dick Schaefer, Loma Linda's director of community relations, the medical center remained committed late last
Reporting Research Misconduct in the Medical Literature
Authors: Robert Steinbrook, Rita F. Redberg
Journal: JAMA Internal Medicine (2015)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
210. Permanent Correction of Leptin Deficiency through Cutaneous Gene Therapy. Lentivirus but Not Retrovirus-Transduced Human Keratinocyte Orthotopic Grafts Achieve Therapeutic Systemic Leptin Levels
Authors: Laura Rico, Isabel Mirones, Blanca Duarte, Almudena Holguin, Antonio Bernad, Marcela Del Rio, Fernando Larcher
Journal: Molecular Therapy (2006)

Leptin deficiencies are involved in rare cases of inherited human obesity and in various forms of lipodystrophy. Previous results from our laboratory showed the feasibility of leptin deficiency correction in the ob/ob mice model using skin grafts from transgenic mice expressing leptin from the epidermis. In spite of epidermal stem cell targeting, several attempts to achieve permanent correction of leptin-deficient ob/ob mice through oncortetrovirus-transduced human keratinocyte (HK) grafts resulted unsuccessful. When human keratinocytes were transduced with a leptin-ires GFP-encoding HIV- derived lentivirus, leptin levels in culture were 3-fold higher that those achieved with oncoretrovirus-transduced HK. Consistently, immunodeficient ob/ob mice orthotopically grafted with lentivirus- transduced HK as part of bioengineered skins, showed therapeutic serum leptin levels. Phenotypic correction of engrafted ob/ob (immunodeficient) mice included weight loss, decreased food intake and normalization of blood glucose. Permanent correction (longer than 22 weeks post-grafting) was achieved in two animals. Skin regenerated form leptin lentivirus-transduced HK displayed histological features similar to those of native human skin. This is the first report of the long-sought sustained correction of a systemic protein deficiency using orthotopic grafting of ex vivo genetically modified human keratinocytes acting as a bioreactor.
Pharmacology and Clinical Toxicity of 4'-Iodo-4'-deoxydoxorubicin: An Example of Successful Application of Pharmacokinetics to Dose Escalation in Phase I Trials
Authors: L. Gianni, L. Vigano, A. Surbone, D. Ballinari, P. Casali, C. Tarella, J. M. Collins, G. Bonadonna
Journal: JNCI Journal of the National Cancer Institute (1990)

Journal Article Pharmacology and Clinical Toxicity of 4′-Iodo-4′-deoxydoxorubicin: An Example of Successful Application of Pharmacokinetics to Dose Escalation in Phase I Trials Get access Luca Gianni, Luca Gianni * Laboratory of Clinical Pharmacology and Division of Medical Oncology, Istituto Nazionale TumoriMilan, Italy *Correspondence to : Luca Gianni, M.D., Laboratory of Clinical Pharmacology, Division of Medical Oncology, Istituto Nazionale Tumori, Via Venezian 1, 20133, Milan, Italy. Search for other works by this author on: Oxford Academic PubMed Google Scholar Lucia Viganò, Lucia Viganò Laboratory of Clinical Pharmacology and Division of Medical Oncology, Istituto Nazionale TumoriMilan, Italy Search for other works by this author on: Oxford Academic PubMed Google Scholar Antonella Surbone, Antonella Surbone Laboratory of Clinical Pharmacology and Division of Medical Oncology, Istituto Nazionale TumoriMilan, Italy Search for other works by this author on: Oxford Academic PubMed Google Scholar Dario Ballinari, Dario Ballinari Farmitalia Carlo ErbaMilan, Italy Search for other works by this author on: Oxford Academic PubMed Google Scholar Paolo Casali, Paolo Casali Laboratory of Clinical Pharmacology and Division of Medical Oncology, Istituto Nazionale TumoriMilan, Italy Search for other works by this author on: Oxford Academic PubMed Google Scholar Corrado Tarella, Corrado Tarella Institute of Haematology, University of TurinTurin, Italy Search for other works by this author on: Oxford Academic PubMed Google Scholar Jerry M. Collins, Jerry M. Collins Food and Drug AdministrationRockville, MD Search for other works by this author on: Oxford Academic PubMed Google Scholar Gianni Bonadonna Gianni Bonadonna Laboratory of Clinical Pharmacology and Division of Medical Oncology, Istituto Nazionale TumoriMilan, Italy Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 82, Issue 6, 21 March 1990, Pages 469–477, https://doi.org/10.1093/jnci/82.6.469 Published: 21 March 1990 Article history Received: 18 September 1989 Revision received: 01 December 1989 Accepted: 08 December 1989 Published: 21 March 1990
Dialysis in Diabetics
Authors: Bernard I. Chazan
Journal: JAMA (1969)

Our experience with peritioneal dialysis and hemodialysis in diabetic patients in the Joslin Clinic for the period 1959 to 1968 shows that 44 patients received dialysis; 32 for anasarca secondary to diabetic nephropathy and congestive heart failure, 7 for an acute exacerbation of chronic renal failure, and 5 for acute renal failure. Diffuse and nodular glomerulosclerosis was found in 19 of the 26 cases with autopsies or biopsies. Best results were obtained in three patients with acute tubular necrosis following diabetic acidosis, in one patient with glutethimide intoxication, and in two patients with chronic renal disease in whom therapy was maintained with long-term hemodialysis (one of whom had successful renal transplantation). Complications of induced hyperglycemia were easily regulated by frequent injections of small amounts of regular insulin. The presence of diabetes should not contraindicate dialysis, especially in those with acute renal failure.
DNA vaccine VGX-3100 with electroporation induces regression of cervical intraepithelial neoplasia 2/3 and clears HPV infection with robust T cell responses: results of a randomized, double-blind, placebo-controlled Phase II trial
Authors: Laurent Humeau, Cornelia Trimble, Matthew Morrow, Xuefei Shen, Michael Dallas, David Weiner, Jean Boyer, Jian Yan, Kimberly Kraynyak, Albert Sylvester, Mary Giffear, Kathy Marcozzi-Pierce, Divya Shah, Kate Broderick, Amir Khan, Jessica Lee, Niranjan Sardesai, Mark Bargarazzi
Journal: Journal for ImmunoTherapy of Cancer (2014)

Meeting abstracts The Phase II study, designated HPV-003 ([NCT01304524][1]), assessed the safety and efficacy of VGX-3100 in 167 women with biopsy-proven cervical intraepithelial neoplasia (CIN) 2 or CIN 3 and HPV-16 or -18. The randomized, placebo-controlled, double-blind study, was stratified by
Thrombostatin, a bradykinin metabolite, reduces platelet activation in a model of arterial wall injury
Authors: A Prieto
Journal: Cardiovascular Research (2002)

Objective: Thrombin activates platelets and contributes to the occlusion of arteries following thrombolytic therapy or angioplasty. Thrombostatin (RPPGF), the angiotensin converting enzyme degradation product of bradykinin, inhibits α-thrombin induced platelet activation. We hypothesized that thrombostatin prevents platelet aggregation and adhesion after balloon angioplasty (BA). Methods: Platelet-rich plasma (PRP) was obtained from 22 Beagle dogs before sacrifice and 10% of the PRP was labeled with 111In. Carotid arteries were then removed from each dog and mounted in a dual perfusion chamber and intimal injury was performed with BA. 111In-PRP with or without thrombostatin or aspirin alone was perfused through the arteries for 60 min. During perfusion, platelet volume was measured using a Coulter counter and a laser-light scattering technique. Platelet adhesion to arteries was measured by radioactivity count. Results: Arterial injury alone compared to non-injury increased platelet volume in the circuit by 1.4 times (×) (P<0.05) using a Coulter counter or 1.8× (P<0.05) using laser-light scattering and increased platelet adhesion by 2.3× (P<0.01). When compared to BA injury alone, the addition of thrombostatin reduced platelet volume by 1.8× (P<0.03) as measured by Coulter counter or 1.9× (P<0.01) by laser-light scattering and platelet adhesion by 4.2× (P<0.05). Compared to BA injury alone, aspirin reduced platelet volume by 1.2× (P<0.01) as assessed by Coulter counter or 1.5× (P<0.03) using laser-light scattering and platelet adhesion by 1.8× (P<0.02). Conclusion: Thrombostatin or aspirin independently decreases evidence of platelet activation in the canine carotid artery model of BA injury.
Myocardial Bridging in a Patient With Exertional Chest Pain
Authors: Maria Stathaki, Antigoni Velidaki, Sophia Koukouraki, Emmanouil Skalidis, Panagiotis Vardas, Nikolaos Karkavitsas
Journal: Clinical Nuclear Medicine (2005)

A 37-year-old man reported exertional chest pain. He smoked for years but had no other risk factors for coronary artery disease. Myocardial perfusion tomography showed a reversible lesion in the anterior and the apical inferior wall of the left ventricle. On cardiac catheterization, coronary arteries were normal during diastolic frames, but the midportion of the left anterior descending coronary artery showed a high-grade stenosis during systole. This “milking effect” and “stepdown–stepup” phenomenon is typical of myocardial bridging, produced by systolic compression of an epicardial coronary artery that has an abnormal intramural course. Beta-blockers are the first-line therapy in myocardial bridging because of their negative inotropic effect (reduced compression of the tunneled segment of the coronary artery) and negative chronotropic effect (longer diastolic period and consequently greater diastolic blood flow), whereas surgical myotomy and stenting are alternative treatment strategies for cases not responding to medical treatment. The patient was treated with a beta-blocker using 100 mg/day metoprolol, and angina was no longer present. Repeat stress myocardial imaging was normal.
In vivo regulation of beta-adrenergic receptors on mononuclear leukocytes and heart. Assessment of receptor compartmentation after agonist infusion and acute aortic constriction in guinea pigs.
Authors: A S Maisel, M G Ziegler, S Carter, P A Insel, H J Motulsky
Journal: Journal of Clinical Investigation (1988)

In animals injected with a bolus of isoproterenol, beta-adrenergic receptors in both mononuclear leukocytes (MNL) and heart were sequestered away from the cell surface, and the time course (0-120 min) and dose-response patterns were similar in the two tissues. In guinea pigs given a constant infusion of isoproterenol, 0.15 mg/(kg.h), down-regulation of total receptor number occurred more quickly and to a greater extent in the MNL than in the heart. We also compared receptor sequestration after aortic constriction-induced acute heart failure. Negligible sequestration (9%) of beta-adrenergic receptors occurred in the MNL of animals treated in this manner, whereas the number of receptors in the sarcolemmal fraction decreased 61%. This selective sequestration of cardiac receptors may result from the action of high concentrations of norepinephrine (which is selective for beta 1 over beta 2 receptors) present at sympathetic nerve-cardiac cell synapses. We conclude that although receptor redistribution occurs similarly in MNL and heart in response to a circulating nonselective agonist, beta-adrenergic receptor redistribution may occur selectively in the heart in response to such stimuli as aortic constriction-induced acute heart failure that activate the sympathetic nervous system.
Nanoparticles Based Stem Cell Tracking in Regenerative Medicine
Authors: Matthew Edmundson, Nguyen TK Thanh, Bing Song
Journal: Theranostics (2013)

Stem cell therapies offer great potentials in the treatment for a wide range of diseases and conditions. With so many stem cell replacement therapies going through clinical trials currently, there is a great need to understand the mechanisms behind a successful therapy, and one of the critical points of discovering them is to track stem cell migration, proliferation and differentiation in vivo. To be of most use tracking methods should ideally be non-invasive, high resolution and allow tracking in three dimensions. Magnetic resonance imaging (MRI) is one of the ideal methods, but requires a suitable contrast agent to be loaded to the cells to be tracked, and one of the most wide-spread in stem cell tracking is a group of agents known as magnetic nanoparticles. This review will explore the current use of magnetic nanoparticles in developing and performing stem cell therapies, and will investigate their potential limitations and the future directions magnetic nanoparticle tracking is heading in.
Clinical Trial Registries
Authors: Jeffrey L. Saver
Journal: JAMA (2007)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Sulfur Oxides and Suspended Particulate Matter
Authors: Phil Gunby
Journal: JAMA (1980)

Forest fires, volcanoes, and other natural sources seem likely to continue emitting sulfur compounds into the atmosphere. What the energy crisis will do to the human contribution to this pollution (coal-burning, petroleum-product combustion, smelting, and so on) remains to be seen. But clearly the problem and efforts to control it will remain news (<i>JAMA Medical News</i>239:2107, 1978). For those interested in what has been learned so far, this little book— eighth in a United Nations series on environmental health—summarizes nicely and provides some 300 references. The book is the work of a World Health Organization task force, which for all the virtues of its efforts, stumbles over one of its own recommendations. In effect, all the group's recommendations add up to a plea for continued study of the problem. One recommendation, however, particularly urges review of air-quality criteria at least every five years to consider what has been learned
Dietary Fiber and Colorectal Cancer
Authors: John A. Baron
Journal: JAMA (2005)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Abstract 2288: Genetic and epigenetic inactivation of miR-31 in EBV-associated nasopharyngeal carcinoma
Authors: Chartia Ching-Mei Cheung, Grace Tin-Yun Chung, Samantha Wei-Man Lun, Kwong-Wai Choy, Ka-Fai To, Kwok-Wai Lo
Journal: Cancer Research (2012)

Abstract Nasopharyngeal carcinoma (NPC) is an Epstein-Barr virus-associated malignant cancer prevalent in Southern China and South-eastern Asia. In this study, we aim to elucidate the fundamental role of aberrant expressed microRNAs (miRNA) in NPC tumorigenesis. By comparison of miRNA expression profiles in NPC tumor lines with non-malignant nasopharyngeal epithelial cell, 119 differentially expressed miRNAs were identified in EBV-associated NPC. Among the 58 microRNAs downregulated in NPC, transcriptional silencing of miR-31 was consistently found in both NPC tumor lines and primary tumors. Expression of miR-31 was detected in none of 6 EBV-positive tumor lines and 38 microdissected primary tumors, but in all normal nasopharyngeal epithelia. Interestingly, miR-31 is located at 0.5 Mb telomeric to CDKN2A at 9p21.3, which is commonly homozygous deleted in NPC. Homozygous deletion of both miR-31 and CDKN2A locus was confirmed in 2 tumor lines. In the 4 tumor lines with intact miR-31, hypermethylation of 5′CpG islands was detected by bisulfate sequencing and MSP analysis. Re-expression of miR-31 was demonstrated in the EBV-positive NPC cell line C666-1 treated with 5-aza-2′-deoxycytidine. The findings suggested that homozygous deletion and promoter methylation are the major mechanisms for transcriptional silencing of miR-31 in NPC. By microarray and bioinformatic analysis, we have identified a number of putative targets of miR-31. Among these candidates, we have proven that miR-31 targeted FIH1 and MCM2 expression in NPC. Ectopic expression of miR-31 in NPC cells resulted in repression of FIH1 and MCM2 protein. Finally, we have demonstrated that restoration of miR-31 or knockdown of FIH1 expression significantly suppressed cell proliferation of C666-1. Our findings indicated that miR-31 is a NPC-associated microRNA which negatively regulates cell growth by repressing FIH1 expression. Citation Format: {Authors}. {Abstract title} [abstract]. In: Proceedings of the 103rd Annual Meeting of the American Association for Cancer Research; 2012 Mar 31-Apr 4; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2012;72(8 Suppl):Abstract nr 2288. doi:1538-7445.AM2012-2288